Welcome to the 2019 HCC Summit, the home of liver cancer research, which will address the latest developments in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) that you as a practicing physician and/or scientist should know. This year, this successful meeting will be held for the first time in Lisbon/Portugal.
There are currently fundamental changes in our understanding of pathophysiology and clinical options in HCC and CCA. After years of stability, we are now facing a multitude of new treatment options, clinical trials and new basic research concepts. While these developments offer many new opportunities for your patients, it is becoming increasingly difficult to keep track and implement these changes into daily clinical practice and research projects in a timely manner. The aim of this multidisciplinary summit is to bring physicians and scientists together and promote the exchange of clinical knowledge, the discussion of controversial issues and the establishment of collaborations.
The program will feature high-end presentations by renowned experts and rising stars covering a broad spectrum of topics, such as:
- New developments in Hepatocellular carcinoma and cholangiocarcinoma management
- Basic and translational research on hepatocellular carcinoma and cholangiocarcinoma
- Immunology and cancer and implications for immunotherapy of HCC/CCA
- Personalized Medicine
- The increasing challenge of metabolic liver disease (NAFLD/NASH) and liver cancer.
- Novel biomarker concepts in HCC and CCA
- Discussions on clinical trials between science, pharma and regulators
Special emphasis will be placed on involving young clinicians and scientists, who will have the opportunity to gain a compact overview of the field and build new networks by easily getting in touch with advanced scientists and key opinion leaders. The meeting offers many opportunities to share your research results and clinical ideas and to get new inspiration for your own career.
We kindly invite you to come to Lisbon and get involved into the future of Liver Cancer.
The Scientific Organising Committee
Sandrine Faivre, Tom Luedde and Maria Reig
View the online programme.
- Presentations by key opinion leaders in liver cancer
- Room for audience engagement and discussion
- Balance of clinical and basic research topics
Who should attend
- Clinicians and scientists from all fields related to liver cancer
- Surgeons, physicians, hepatologists, gastroenterologists, radiologists, biologists, oncologists, basic scientists
- Particularly young clinicians and scientists
“The HCC Summit, Lisbon, Portugal, 14/02/2019-16/02/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 17 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”
“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.
In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:
14.02.2019 – 5,00
15.02.2019 – 8,00
16.02.2019 – 4,00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.